Use	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
:	O
II	O
.	O

Clinical	O
efficacy	O
and	O
pharmacokinetics	O
in	O
relapsed	O
patients	O
.	O

The	O
therapeutic	O
effect	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
was	O
evaluated	O
among	O
15	O
APL	O
patients	O
at	O
relapse	O
after	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
induced	O
and	O
chemotherapy	O
maintained	O
complete	O
remission	O
(	O
CR	O
)	O
.	O

As2O3	O
was	O
administered	O
intravenously	O
at	O
the	O
dose	O
of	O
10	O
mg/d	O
.	O

Clinical	O
CR	O
was	O
achieved	O
in	O
nine	O
of	O
10	O
(	O
90	O
%	O
)	O
patients	O
treated	O
with	O
As2O3	O
alone	O
and	O
in	O
the	O
remaining	O
five	O
patients	O
treated	O
by	O
the	O
combination	O
of	O
As2O3	O
and	O
low-dose	O
chemotherapeutic	O
drugs	O
or	O
ATRA	O
.	O

During	O
the	O
treatment	O
with	O
As2O3	O
,	O
there	O
was	O
no	O
bone	O
marrow	O
depression	O
and	O
only	O
limited	O
side	O
effects	O
were	O
encountered	O
.	O

Pharmacokinetic	O
studies	O
,	O
which	O
were	O
performed	O
in	O
eight	O
patients	O
,	O
showed	O
that	O
after	O
a	O
peak	O
level	O
of	O
5.54	O
micromol/L	O
to	O
7.30	O
micromol/L	O
,	O
plasma	O
arsenic	O
was	O
rapidly	O
eliminated	O
,	O
and	O
the	O
continuous	O
administration	O
of	O
As2O3	O
did	O
not	O
alter	O
its	O
pharmacokinetic	O
behaviors	O
.	O

In	O
addition	O
,	O
increased	O
amounts	O
of	O
arsenic	O
appeared	O
in	O
the	O
urine	O
,	O
with	O
a	O
daily	O
excretion	O
accounting	O
for	O
approximately	O
1	O
%	O
to	O
8	O
%	O
of	O
the	O
total	O
daily	O
dose	O
administered	O
.	O

Arsenic	O
contents	O
in	O
hair	O
and	O
nail	O
were	O
increased	O
,	O
and	O
the	O
peak	O
content	O
of	O
arsenic	O
could	O
reach	O
2.5	O
to	O
2.7	O
microg/g	O
tissue	O
at	O
CR	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
decline	O
of	O
the	O
arsenic	O
content	O
in	O
hair	O
and	O
nail	O
was	O
observed	O
after	O
withdrawal	O
of	O
the	O
drug	O
.	O

We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Use	NULL
of	NULL
Arsenic	NULL
Trioxide	NULL
(	NULL
As	NULL
;	NULL
0	NULL
;	NULL
)	NULL
in	NULL
the	NULL
Treatment	NULL
of	NULL
Acute	NULL
Promyelocytic	NULL
Leukemia	NULL
(	NULL
APL	NULL
)	NULL
:	NULL
II	NULL
.	NULL

Clinical	NULL
Efficacy	NULL
and	NULL
Pharmacokinetics	NULL
in	NULL
Relapsed	NULL
Patients	NULL
By	NULL
Zhi-Xiang	NULL
Shen	NULL
,	NULL
Guo-Qiang	NULL
Chen	NULL
,	NULL
Jian-Hua	NULL
Ni	NULL
,	NULL
Xiu-Shong	NULL
Li	NULL
,	NULL
Shu-Min	NULL
Xiong	NULL
,	NULL
Qian-Yao	NULL
Qiu	NULL
,	NULL
Jun	NULL
Zhu	NULL
,	NULL
Wei	NULL
Tang	NULL
,	NULL
Guan-Lin	NULL
Sun	NULL
,	NULL
Kan-Qi	NULL
Yang	NULL
,	NULL
Yu	NULL
Chen	NULL
,	NULL
Li	NULL
Zhou	NULL
,	NULL
Zhi-Wen	NULL
Fang	NULL
,	NULL
Yan-Ting	NULL
Wang	NULL
,	NULL
Jun	NULL
Ma	NULL
,	NULL
Peng	NULL
Zhang	NULL
,	NULL
Ting-Dong	NULL
Zhang	NULL
,	NULL
Sai-Juan	NULL
Chen	NULL
,	NULL
Zhu	NULL
Chen	NULL
,	NULL
and	NULL
Zhen-¥i	NULL
Wang	NULL
The	NULL
therapeutic	NULL
effect	NULL
of	NULL
arsenic	NULL
trioxide	NULL
(	NULL
As	NULL
;	NULL
0	NULL
;	NULL
)	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
was	NULL
evaluated	NULL
among	NULL
15	NULL
APL	NULL
patients	NULL
at	NULL
relapse	NULL
after	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
induced	NULL
and	NULL
chemotherapy	NULL
maintained	NULL
complete	NULL
remission	NULL
(	NULL
CR	NULL
}	NULL
.	NULL

As,0	NULL
;	NULL
was	NULL
administered	NULL
intravenously	NULL
at	NULL
the	NULL
dose	NULL
of	NULL
10	NULL
mg/d	NULL
.	NULL

Clinical	NULL
CR	NULL
was	NULL
achieved	NULL
in	NULL
nine	NULL
of	NULL
10	NULL
(	NULL
90	NULL
%	NULL
)	NULL
patients	NULL
treated	NULL
with	NULL
As	NULL
;	NULL
0	NULL
;	NULL
alone	NULL
and	NULL
in	NULL
the	NULL
remaining	NULL
five	NULL
patients	NULL
treated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
and	NULL
low-dose	NULL
chemotherapeutic	NULL
drugs	NULL
or	NULL
ATRA	NULL
.	NULL

During	NULL
the	NULL
treatment	NULL
with	NULL
As,0	NULL
;	NULL
,	NULL
there	NULL
was	NULL
no	NULL
bone	NULL
marrow	NULL
depression	NULL
and	NULL
only	NULL
limited	NULL
side	NULL
effects	NULL
were	NULL
encountered	NULL
.	NULL

Pharmacokinetic	NULL
studies	NULL
,	NULL
which	NULL
were	NULL
performed	NULL
in	NULL
eight	NULL
patients	NULL
,	NULL
showed	NULL
that	NULL
after	NULL
a	NULL
peak	NULL
level	NULL
of	NULL
5.54	NULL
pmol/L	NULL
to	NULL
7.30	NULL
pmol/L	NULL
,	NULL
plasma	NULL
RSENIC	NULL
HAS	NULL
BEEN	NULL
considered	NULL
to	NULL
be	NULL
a	NULL
poison	NULL
for	NULL
a	NULL
long	NULL
time	NULL
.	NULL

Since	NULL
the	NULL
1820s	NULL
,	NULL
it	NULL
has	NULL
been	NULL
generally	NULL
accepted	NULL
as	NULL
a	NULL
potent	NULL
environmental	NULL
cocarcinogen	NULL
for	NULL
some	NULL
human	NULL
malignancies	NULL
,	NULL
especially	NULL
for	NULL
skin	NULL
and	NULL
lung	NULL
cancers	NULL
.	NULL
'	NULL

''	NULL
However	NULL
,	NULL
arsenic	NULL
compounds	NULL
have	NULL
also	NULL
been	NULL
used	NULL
for	NULL
medical	NULL
purposes	NULL
.	NULL

In	NULL
Traditional	NULL
Chinese	NULL
Medicine	NULL
,	NULL
arsenous	NULL
acid	NULL
or	NULL
arsenic	NULL
trioxide	NULL
paste	NULL
is	NULL
often	NULL
used	NULL
to	NULL
treat	NULL
tooth	NULL
marrow	NULL
disease	NULL
as	NULL
a	NULL
devitalizing	NULL
agent	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
used	NULL
against	NULL
some	NULL
other	NULL
diseases	NULL
such	NULL
as	NULL
psoriasis	NULL
,	NULL
syphilis	NULL
,	NULL
and	NULL
rheu-matosis	NULL
with	NULL
the	NULL
principal	NULL
of	NULL
``	NULL
using	NULL
a	NULL
toxic	NULL
against	NULL
another	NULL
toxic	NULL
.	NULL
``	NULL

''	NULL
In	NULL
ancient	NULL
Greek	NULL
and	NULL
Roman	NULL
times	NULL
,	NULL
arsenic	NULL
was	NULL
used	NULL
as	NULL
both	NULL
therapeutic	NULL
agent	NULL
and	NULL
poison	NULL
.	NULL

In	NULL
Western	NULL
medicine	NULL
,	NULL
arsenic	NULL
was	NULL
used	NULL
more	NULL
recently	NULL
(	NULL
until	NULL
the	NULL
advent	NULL
of	NULL
penicil-lin	NULL
)	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
syphilis	NULL
and	NULL
as	NULL
a	NULL
tonic	NULL
in	NULL
Fowler	NULL
's	NULL
solution	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
known	NULL
carcinogenic	NULL
effect	NULL
,	NULL
its	NULL
only	NULL
therapeutic	NULL
use	NULL
today	NULL
is	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
trypanosomiasis	NULL
involving	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
.	NULL
``	NULL

In	NULL
the	NULL
1970s	NULL
,	NULL
arsenic	NULL
trioxide	NULL
(	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
)	NULL
was	NULL
introduced	NULL
into	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
and	NULL
From	NULL
Shanghai	NULL
Institute	NULL
of	NULL
Hematology	NULL
,	NULL
Department	NULL
of	NULL
Hematology	NULL
,	NULL
Rui-Jin	NULL
Hospital	NULL
and	NULL
Ren-Ji	NULL
Hospital	NULL
,	NULL
Shanghai	NULL
Second	NULL
Medical	NULL
University	NULL
,	NULL
Shanghai	NULL
,	NULL
P.R	NULL
.	NULL

China	NULL
;	NULL
Harbin	NULL
Institute	NULL
of	NULL
Hematology	NULL
,	NULL
Harbin	NULL
Municipal	NULL
First	NULL
People	NULL
's	NULL
Hospital	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Traditional	NULL
Chinese	NULL
Medicine	NULL
,	NULL
First	NULL
Hospital	NULL
affiliated	NULL
to	NULL
Harbin	NULL
Medical	NULL
University	NULL
,	NULL
Harbin	NULL
,	NULL
P.R	NULL
.	NULL

China	NULL
.	NULL

Submitted	NULL
July	NULL
30	NULL
,	NULL
1996	NULL
;	NULL
accepted	NULL
December	NULL
13	NULL
,	NULL
1996	NULL
.	NULL

Supported	NULL
on	NULL
part	NULL
by	NULL
National	NULL
Natural	NULL
Science	NULL
Foundation	NULL
of	NULL
China	NULL
(	NULL
NSCF	NULL
)	NULL
,	NULL
Shanghai	NULL
Municipal	NULL
Foundation	NULL
for	NULL
Science	NULL
and	NULL
Technology	NULL
,	NULL
National	NULL
Ministry	NULL
of	NULL
Public	NULL
Health	NULL
,	NULL
Shanghai	NULL
Municipal	NULL
Foundation	NULL
for	NULL
Outstanding	NULL
Young	NULL
Researcher	NULL
,	NULL
and	NULL
Clyde	NULL
Wu	NULL
Foundation	NULL
of	NULL
Shanghai	NULL
Institute	NULL
of	NULL
Hematology	NULL
.	NULL

Z-X.8	NULL
.	NULL

and	NULL
G.-Q.C	NULL
.	NULL

should	NULL
be	NULL
considered	NULL
as	NULL
equal	NULL
first	NULL
authors	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Zhu	NULL
Chen	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Shanghai	NULL
Institute	NULL
of	NULL
Hematology	NULL
,	NULL
Ruijin	NULL
Hospital	NULL
,	NULL
Shanghai	NULL
Second	NULL
Medical	NULL
University	NULL
,	NULL
197	NULL
Ruijin	NULL
Road	NULL
II	NULL
,	NULL
Shanghai	NULL
,	NULL
200025	NULL
,	NULL
China	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/97/8909-0008	NULL
$	NULL
3.00/0	NULL
3354	NULL
arsenic	NULL
was	NULL
rapidly	NULL
eliminated	NULL
,	NULL
and	NULL
the	NULL
continuous	NULL
administration	NULL
of	NULL
As,0	NULL
;	NULL
did	NULL
not	NULL
alter	NULL
its	NULL
pharmacokinetic	NULL
behaviors	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
increased	NULL
amounts	NULL
of	NULL
arsenic	NULL
appeared	NULL
in	NULL
the	NULL
urine	NULL
,	NULL
with	NULL
a	NULL
daily	NULL
excretion	NULL
accounting	NULL
for	NULL
approximately	NULL
1	NULL
%	NULL
to	NULL
8	NULL
%	NULL
of	NULL
the	NULL
total	NULL
daily	NULL
dose	NULL
administered	NULL
.	NULL

Arsenic	NULL
contents	NULL
in	NULL
hair	NULL
and	NULL
nail	NULL
were	NULL
increased	NULL
,	NULL
and	NULL
the	NULL
peak	NULL
content	NULL
of	NULL
arsenic	NULL
could	NULL
reach	NULL
2.5	NULL
to	NULL
2.7	NULL
mg/g	NULL
tissue	NULL
at	NULL
CR	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
a	NULL
decline	NULL
of	NULL
the	NULL
arsenic	NULL
content	NULL
in	NULL
hair	NULL
and	NULL
nail	NULL
was	NULL
observed	NULL
after	NULL
withdrawal	NULL
of	NULL
the	NULL
drug	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
treatment	NULL
is	NULL
an	NULL
effective	NULL
and	NULL
relatively	NULL
safe	NULL
drug	NULL
in	NULL
APL	NULL
patients	NULL
refractory	NULL
to	NULL
ATRA	NULL
and	NULL
conventional	NULL
chemo-therapy	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

showed	NULL
a	NULL
striking	NULL
effectiveness	NULL
in	NULL
the	NULL
Northeastern	NULL
region	NULL
of	NULL
China	NULL
.	NULL

The	NULL
clinical	NULL
complete	NULL
remission	NULL
(	NULL
CR	NULL
)	NULL
rate	NULL
with	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
(	NULL
10	NULL
mg/d	NULL
,	NULL
intravenous	NULL
[	NULL
IV	NULL
]	NULL
infusion	NULL
for	NULL
28	NULL
to	NULL
60	NULL
days	NULL
)	NULL
was	NULL
reportedly	NULL
from	NULL
65.6	NULL
%	NULL
to	NULL
84	NULL
%	NULL
.	NULL

Moreover	NULL
,	NULL
28.2	NULL
%	NULL
(	NULL
9/32	NULL
)	NULL
of	NULL
the	NULL
patients	NULL
had	NULL
a	NULL
survival	NULL
of	NULL
over	NULL
10	NULL
years	NULL
,	NULL
and	NULL
most	NULL
patients	NULL
showed	NULL
neither	NULL
bone	NULL
marrow	NULL
depression	NULL
nor	NULL
other	NULL
severe	NULL
clinical	NULL
side	NULL
effects	NULL
during	NULL
the	NULL
treatment	NULL
.	NULL
``	NULL

''	NULL
In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
present	NULL
clinical	NULL
results	NULL
and	NULL
pharmacokinetics	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
among	NULL
15	NULL
cases	NULL
of	NULL
relapsed	NULL
APL	NULL
patients	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
As	NULL
;	NULL
0	NULL
;	NULL
is	NULL
a	NULL
very	NULL
effective	NULL
and	NULL
relatively	NULL
safe	NULL
drug	NULL
for	NULL
remission	NULL
induction	NULL
in	NULL
relapsed	NULL
APL	NULL
.	NULL

PATIENTS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
.	NULL

-	NULL
Fifteen	NULL
cases	NULL
of	NULL
relapsed	NULL
APL	NULL
entered	NULL
into	NULL
this	NULL
study	NULL
between	NULL
December	NULL
1994	NULL
and	NULL
April	NULL
1996	NULL
.	NULL

The	NULL
diagnosis	NULL
was	NULL
based	NULL
on	NULL
clinical	NULL
data	NULL
(	NULL
history	NULL
,	NULL
symptoms	NULL
,	NULL
and	NULL
physical	NULL
findings	NULL
)	NULL
,	NULL
examination	NULL
of	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
(	NULL
BM	NULL
)	NULL
according	NULL
to	NULL
FAB	NULL
classification	NULL
,	NULL
the	NULL
karyotype	NULL
,	NULL
and	NULL
RT-PCR	NULL
analysis	NULL
for	NULL
PML-RARa	NULL
transcripts	NULL
,	NULL
which	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
our	NULL
previously	NULL
described	NULL
methods	NULL
.	NULL
``	NULL

All	NULL
patients	NULL
'	NULL
main	NULL
clinical	NULL
data	NULL
at	NULL
diagnosis	NULL
were	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Protocol	NULL
therapy	NULL
.	NULL

-	NULL
As	NULL
,	NULL
O	NULL
;	NULL
solution	NULL
,	NULL
0.1	NULL
%	NULL
(	NULL
10	NULL
mg	NULL
in	NULL
10	NULL
mL	NULL
)	NULL
,	NULL
was	NULL
prepared	NULL
by	NULL
the	NULL
Pharmacy	NULL
of	NULL
Traditional	NULL
Chinese	NULL
Medicine	NULL
in	NULL
the	NULL
First	NULL
Hospital	NULL
affiliated	NULL
to	NULL
Harbin	NULL
Medical	NULL
University	NULL
(	NULL
Harbin	NULL
,	NULL
P.R	NULL
.	NULL

China	NULL
)	NULL
.	NULL

The	NULL
bulk	NULL
material	NULL
used	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
injectable	NULL
solution	NULL
was	NULL
As,0	NULL
;	NULL
,	NULL
,	NULL
with	NULL
a	NULL
purity	NULL
of	NULL
more	NULL
than	NULL
99	NULL
%	NULL
,	NULL
made	NULL
by	NULL
Beijing	NULL
Chemical	NULL
Industry	NULL
Company	NULL
,	NULL
China	NULL
.	NULL

For	NULL
these	NULL
15	NULL
patients	NULL
,	NULL
the	NULL
following	NULL
treatment	NULL
protocol	NULL
was	NULL
given	NULL
:	NULL
10	NULL
mg	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
(	NULL
10	NULL
mL	NULL
0.1	NULL
%	NULL
solution	NULL
)	NULL
was	NULL
added	NULL
into	NULL
500	NULL
mL	NULL
5	NULL
%	NULL
glucose-normal	NULL
saline	NULL
solution	NULL
for	NULL
IV	NULL
drip	NULL
over	NULL
2	NULL
to	NULL
3	NULL
hours	NULL
once	NULL
a	NULL
day	NULL
.	NULL

The	NULL
protocol	NULL
was	NULL
approved	NULL
by	NULL
the	NULL
Ethic	NULL
Committee	NULL
of	NULL
Rui-Jin	NULL
Hospital	NULL
,	NULL
Shanghai	NULL
Second	NULL
Medical	NULL
University	NULL
and	NULL
informed	NULL
consent	NULL
was	NULL
obtained	NULL
from	NULL
all	NULL
patients	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
need	NULL
to	NULL
control	NULL
the	NULL
hyperleukocytosis	NULL
(	NULL
WBC	NULL
>	NULL
30	NULL
X	NULL
10°/L	NULL
)	NULL
in	NULL
three	NULL
patients	NULL
,	NULL
low-dose	NULL
chemotherapy	NULL
was	NULL
added	NULL
for	NULL
a	NULL
few	NULL
days	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
two	NULL
cases	NULL
,	NULL
low-dose	NULL
ATRA	NULL
(	NULL
30	NULL
mg/d	NULL
)	NULL
was	NULL
added	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Blood	NULL
counts	NULL
were	NULL
performed	NULL
at	NULL
least	NULL
twice	NULL
a	NULL
week	NULL
for	NULL
all	NULL
patients	NULL
.	NULL

Sequential	NULL
measurements	NULL
of	NULL
coagulation	NULL
and	NULL
fibrinolysis	NULL
,	NULL
including	NULL
factor	NULL
VIII	NULL
:	NULL
C	NULL
,	NULL
von	NULL
Willebrand	NULL
factor	NULL
,	NULL
fibrino-gen	NULL
,	NULL
plasminogen	NULL
,	NULL
D-D	NULL
dimers	NULL
,	NULL
fibrin	NULL
degradation	NULL
product	NULL
(	NULL
FDP	NULL
)	NULL
,	NULL
tissue-plasminogen	NULL
activator	NULL
,	NULL
plasminogen	NULL
activator	NULL
inhibitor	NULL
(	NULL
PAX	NULL
)	NULL
,	NULL
and	NULL
antithrombin-III	NULL
(	NULL
AT-III	NULL
)	NULL
,	NULL
were	NULL
performed	NULL
in	NULL
four	NULL
patients	NULL
.	NULL

BM	NULL
examination	NULL
was	NULL
performed	NULL
every	NULL
week	NULL
and/or	NULL
at	NULL
the	NULL
time	NULL
of	NULL
response	NULL
evaluation	NULL
.	NULL

CR	NULL
was	NULL
defined	NULL
by	NULL
the	NULL
percentage	NULL
of	NULL
APL	NULL
blasts	NULL
Blood	NULL
,	NULL
Vol	NULL
89	NULL
,	NULL
No	NULL
9	NULL
(	NULL
May	NULL
1	NULL
)	NULL
,	NULL
1997	NULL
:	NULL
pp	NULL
3354-3360	NULL
EFFICACY	NULL
AND	NULL
PHARMACOKINETICS	NULL
OF	NULL
ARSENIC	NULL
IN	NULL
TREATING	NULL
APL	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Patients	NULL
'	NULL
Clinical	NULL
Data	NULL
at	NULL
Diagnosis	NULL
3355	NULL
Previous	NULL
Treatment	NULL
Protocol	NULL
Patient	NULL
HB	NULL
WBC	NULL
Platelet	NULL
APL	NULL
Cell	NULL
%	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
/PML-No	NULL
.	NULL

Sex/Age	NULL
(	NULL
g/L	NULL
)	NULL
(	NULL
x10	NULL
%	NULL
/L	NULL
)	NULL
(	NULL
x109/L	NULL
in	NULL
BM	NULL
RARe	NULL
:	NULL
CR-Induction	NULL
Consolidation	NULL
1	NULL
F/40	NULL
107.0	NULL
0.9	NULL
8.4	NULL
39.5	NULL
+/ND	NULL
ATRA	NULL
(	NULL
40	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
HA	NULL
+	NULL
DA	NULL
2	NULL
M/34	NULL
138.0	NULL
3.3	NULL
8.6	NULL
96.0	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
40	NULL
mg	NULL
x	NULL
22	NULL
d	NULL
)	NULL
HA	NULL
+	NULL
DA	NULL
+	NULL
AA	NULL
3	NULL
M/41	NULL
84.0	NULL
0.8	NULL
52.0	NULL
19.5	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
30	NULL
mg	NULL
x	NULL
51	NULL
d	NULL
)	NULL
HA	NULL
+	NULL
AA	NULL
4	NULL
M/43	NULL
76.0	NULL
3.4	NULL
56.9	NULL
32.0	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
40	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
HA	NULL
+	NULL
AA	NULL
5	NULL
M/34	NULL
126.0	NULL
1.5	NULL
7.1	NULL
70.0	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
60	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
AA	NULL
6	NULL
F/15	NULL
108.0	NULL
51.0	NULL
4.0	NULL
95.0	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
30	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
DA	NULL
7	NULL
M/53	NULL
75.0	NULL
4.0	NULL
5.0	NULL
85.0	NULL
-/	NULL
[	NULL
L	NULL
(	NULL
-	NULL
)	NULL
S	NULL
(	NULL
-	NULL
)	NULL
ATRA	NULL
(	NULL
80	NULL
mg	NULL
x	NULL
70	NULL
d	NULL
)	NULL
HA	NULL
+	NULL
ATRA	NULL
8	NULL
F/15	NULL
75.0	NULL
3.8	NULL
76.0	NULL
72.0	NULL
ND/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
15	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
DA	NULL
+	NULL
ATRA	NULL
9	NULL
M/32	NULL
112.0	NULL
9.8	NULL
4.8	NULL
59.0	NULL
ND	NULL
ATRA	NULL
(	NULL
60	NULL
mg	NULL
x	NULL
47	NULL
d	NULL
)	NULL
DA	NULL
10	NULL
M/14	NULL
127.0	NULL
3.1	NULL
23.6	NULL
90.0	NULL
ND	NULL
ATRA	NULL
(	NULL
30	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
HA	NULL
11	NULL
F/27	NULL
64.0	NULL
15.2	NULL
48.0	NULL
81.5	NULL
ATRA	NULL
(	NULL
80	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
HA	NULL
ATRA	NULL
(	NULL
60	NULL
mg	NULL
x	NULL
30	NULL
d	NULL
)	NULL
*	NULL
HA	NULL
+	NULL
AA	NULL
+	NULL
DA	NULL
12	NULL
M/42	NULL
115.0	NULL
4.0	NULL
13.6	NULL
12.5	NULL
ND/L	NULL
(	NULL
+	NULL
)	NULL
BHAC-DMP	NULL
MTX	NULL
+	NULL
Ara-c	NULL
BHAC-DMP®*	NULL
MTX	NULL
+	NULL
Ara-c	NULL
ATRA	NULL
(	NULL
70	NULL
mg	NULL
x	NULL
24	NULL
d	NULL
)	NULL
t	NULL
BHAC-DMP	NULL
13	NULL
F/53	NULL
122.0	NULL
4.6	NULL
10.8	NULL
44.0	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
80	NULL
mg	NULL
x	NULL
48	NULL
d	NULL
)	NULL
DA	NULL
+	NULL
HA	NULL
ATRA	NULL
(	NULL
40	NULL
mg	NULL
x	NULL
68	NULL
d	NULL
)	NULL
*	NULL
DA	NULL
14	NULL
M/4g9	NULL
65.0	NULL
0.6	NULL
4.0	NULL
71.0	NULL
ND	NULL
BHAC-DMP	NULL
MTX	NULL
+	NULL
Ara-c	NULL
BHAC-DMP*	NULL
MTX	NULL
+	NULL
Ara-c	NULL
ATRA	NULL
(	NULL
70	NULL
mg	NULL
x	NULL
24	NULL
d	NULL
)	NULL
t	NULL
BHAC-DMP	NULL
15	NULL
M/45	NULL
105.0	NULL
67.5	NULL
4.2	NULL
72.0	NULL
+/L	NULL
(	NULL
+	NULL
)	NULL
ATRA	NULL
(	NULL
30	NULL
mg	NULL
x	NULL
50	NULL
d	NULL
)	NULL
DA	NULL
+	NULL
HA	NULL
Patients	NULL
No	NULL
.	NULL

11	NULL
and	NULL
13	NULL
were	NULL
diagnosed	NULL
at	NULL
second	NULL
relapse	NULL
;	NULL
patients	NULL
No	NULL
.	NULL

12	NULL
and	NULL
15	NULL
were	NULL
diagnosed	NULL
at	NULL
third	NULL
relapse	NULL
;	NULL
all	NULL
other	NULL
cases	NULL
were	NULL
at	NULL
first	NULL
relapse	NULL
.	NULL

For	NULL
PML-RARa	NULL
,	NULL
L	NULL
and	NULL
S	NULL
denote	NULL
the	NULL
long	NULL
and	NULL
short	NULL
type	NULL
isoforms	NULL
of	NULL
the	NULL
fusion	NULL
mRNA	NULL
,	NULL
respectively	NULL
.	NULL
``	NULL

Abbreviations	NULL
:	NULL
ND	NULL
,	NULL
not	NULL
done	NULL
;	NULL
DA	NULL
,	NULL
Daunorubicin	NULL
+	NULL
Ara-C	NULL
;	NULL
HA	NULL
,	NULL
Harringtonin	NULL
+	NULL
Ara-C	NULL
;	NULL
AA	NULL
,	NULL
Aclamycin	NULL
+	NULL
Ara-C	NULL
;	NULL
BHAC-DMP	NULL
,	NULL
Benenoyl-Ara-C	NULL
+	NULL
daunomycin	NULL
+	NULL
6-MP	NULL
+	NULL
Prednisone	NULL
.	NULL

*	NULL
Protocol	NULL
used	NULL
for	NULL
the	NULL
second	NULL
CR	NULL
.	NULL

t	NULL
Protocol	NULL
used	NULL
for	NULL
the	NULL
third	NULL
CR	NULL
.	NULL

<	NULL
5	NULL
%	NULL
in	NULL
the	NULL
BM	NULL
and	NULL
the	NULL
normalization	NULL
of	NULL
blood	NULL
counts	NULL
.	NULL

After	NULL
CR	NULL
,	NULL
the	NULL
treatment	NULL
was	NULL
discontinued	NULL
for	NULL
30	NULL
days	NULL
.	NULL

Then	NULL
a	NULL
second	NULL
course	NULL
of	NULL
As	NULL
;	NULL
,0	NULL
,	NULL
was	NULL
used	NULL
for	NULL
28	NULL
days	NULL
as	NULL
consolidation	NULL
therapy	NULL
.	NULL

To	NULL
estimate	NULL
the	NULL
effect	NULL
of	NULL
As	NULL
;	NULL
0	NULL
,	NULL
on	NULL
normal	NULL
hematopoiesis	NULL
,	NULL
in	NULL
vitro	NULL
culture	NULL
of	NULL
colony-forming	NULL
unit	NULL
granulocyte	NULL
(	NULL
CFU-G	NULL
)	NULL
and	NULL
of	NULL
CFU-	NULL
Table	NULL
2	NULL
.	NULL

Remission	NULL
Induction	NULL
With	NULL
As	NULL
;	NULL
0	NULL
;	NULL
Total	NULL
Doses	NULL
of	NULL
-	NULL
Days	NULL
to	NULL
Patient	NULL
|	NULL
Treatment	NULL
As	NULL
;	NULL
0	NULL
;	NULL
Achieve	NULL
No	NULL
.	NULL

Results	NULL
Used	NULL
CR	NULL
Additional	NULL
Treatment	NULL
1	NULL
CR	NULL
280	NULL
28	NULL
2	NULL
CR	NULL
410	NULL
41	NULL
3	NULL
CR	NULL
280	NULL
28	NULL
4	NULL
CR	NULL
280	NULL
28	NULL
5	NULL
CR	NULL
280	NULL
28	NULL
6	NULL
CR	NULL
300	NULL
30	NULL
7	NULL
NR	NULL
540	NULL
8	NULL
CR	NULL
380	NULL
38	NULL
9	NULL
CR	NULL
440	NULL
44	NULL
10	NULL
CR	NULL
280	NULL
28	NULL
11	NULL
CR	NULL
280	NULL
28	NULL
Daunorubicin	NULL
(	NULL
40	NULL
mg/d	NULL
x	NULL
3	NULL
d	NULL
)	NULL
+	NULL
Ara-C	NULL
(	NULL
150	NULL
mg/d	NULL
x	NULL
5	NULL
d	NULL
)	NULL
12	NULL
CR	NULL
390	NULL
39	NULL
ATRA	NULL
30	NULL
mg/d	NULL
,	NULL
from	NULL
day	NULL
11	NULL
to	NULL
CR	NULL
13	NULL
CR	NULL
530	NULL
53	NULL
Hydroxyurea	NULL
(	NULL
3	NULL
g/d	NULL
x	NULL
15	NULL
d	NULL
)	NULL
14	NULL
CR	NULL
420	NULL
42	NULL
ATRA	NULL
30	NULL
mg/d	NULL
,	NULL
from	NULL
day	NULL
3	NULL
to	NULL
CR	NULL
15	NULL
CR	NULL
540	NULL
54	NULL
Harringtonine	NULL
(	NULL
4	NULL
mg	NULL
x	NULL
25	NULL
d	NULL
)	NULL
+	NULL
Ara-C	NULL
(	NULL
200	NULL
mg/d	NULL
x	NULL
9	NULL
d	NULL
)	NULL
Abbreviation	NULL
:	NULL
NR	NULL
,	NULL
no	NULL
remission	NULL
.	NULL

erythrocyte	NULL
(	NULL
CFU-E	NULL
)	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
standard	NULL
proce-dures	NULL
.	NULL

Pharmacokinetic	NULL
studies	NULL
.	NULL

-	NULL
Plasma	NULL
pharmacokinetic	NULL
studies	NULL
were	NULL
performed	NULL
in	NULL
eight	NULL
patients	NULL
after	NULL
the	NULL
first	NULL
IV	NULL
administration	NULL
of	NULL
As,0	NULL
;	NULL
solution	NULL
.	NULL

Blood	NULL
samples	NULL
were	NULL
collected	NULL
into	NULL
covered	NULL
heparinized	NULL
tubes	NULL
before	NULL
drug	NULL
administration	NULL
and	NULL
thereafter	NULL
at	NULL
0.5	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
12	NULL
,	NULL
and	NULL
24	NULL
hours	NULL
.	NULL

Plasma	NULL
arsenic	NULL
concentrations	NULL
were	NULL
measured	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Pharmacokinetic	NULL
parameters	NULL
,	NULL
including	NULL
maximal	NULL
plasma	NULL
concentration	NULL
(	NULL
Cp	NULL
...	NULL
)	NULL
,	NULL
area	NULL
under	NULL
the	NULL
concentration-time	NULL
curve	NULL
(	NULL
AUC	NULL
)	NULL
,	NULL
half-life	NULL
(	NULL
t1/2	NULL
«	NULL
and	NULL
t1/29	NULL
)	NULL
,	NULL
clearance	NULL
rate	NULL
[	NULL
CL	NULL
(	NULL
8	NULL
)	NULL
]	NULL
,	NULL
and	NULL
apparent	NULL
distribution	NULL
volume	NULL
(	NULL
Ve	NULL
)	NULL
,	NULL
were	NULL
calculated	NULL
using	NULL
computerized	NULL
software	NULL
PK-GRAPH	NULL
made	NULL
by	NULL
the	NULL
Department	NULL
of	NULL
Pharmacology	NULL
,	NULL
Shanghai	NULL
Second	NULL
Medical	NULL
University	NULL
.	NULL
``	NULL

RESULTS	NULL
Treatment	NULL
efficacy	NULL
.	NULL

-	NULL
Fourteen	NULL
of	NULL
15	NULL
patients	NULL
achieved	NULL
CR	NULL
with	NULL
As	NULL
;	NULL
0	NULL
;	NULL
,	NULL
treatment	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
other	NULL
drugs	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Among	NULL
10	NULL
patients	NULL
treated	NULL
with	NULL
As,0	NULL
,	NULL
alone	NULL
(	NULL
Table	NULL
2	NULL
,	NULL
cases	NULL
no	NULL
.	NULL

1-10	NULL
)	NULL
,	NULL
nine	NULL
(	NULL
90	NULL
%	NULL
)	NULL
obtained	NULL
CR	NULL
.	NULL

The	NULL
duration	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
needed	NULL
to	NULL
obtain	NULL
the	NULL
CR	NULL
in	NULL
these	NULL
nine	NULL
patients	NULL
was	NULL
between	NULL
28	NULL
and	NULL
44	NULL
days	NULL
(	NULL
median	NULL
,	NULL
38	NULL
days	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
total	NULL
dose	NULL
of	NULL
the	NULL
drug	NULL
needed	NULL
for	NULL
remission	NULL
induction	NULL
was	NULL
between	NULL
280	NULL
and	NULL
440	NULL
mg	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
in	NULL
patient	NULL
No	NULL
.	NULL

7	NULL
,	NULL
who	NULL
did	NULL
not	NULL
enter	NULL
into	NULL
CR	NULL
after	NULL
53	NULL
days	NULL
of	NULL
continuous	NULL
treatment	NULL
,	NULL
the	NULL
leukemic	NULL
cells	NULL
obtained	NULL
at	NULL
the	NULL
time	NULL
of	NULL
relapse	NULL
had	NULL
no	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
nor	NULL
PML-RARa	NULL
transcripts	NULL
,	NULL
although	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
and	NULL
PML-RARa	NULL
fusion	NULL
gene	NULL
were	NULL
positive	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
the	NULL
disease	NULL
and	NULL
the	NULL
first	NULL
CR	NULL
was	NULL
induced	NULL
by	NULL
ATRA	NULL
.	NULL

In	NULL
the	NULL
remaining	NULL
five	NULL
patients	NULL
,	NULL
CR	NULL
was	NULL
achieved	NULL
with	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3356	NULL
1°	NULL
—_l_H—	NULL
“	NULL
_l__A_LL_—i_l	NULL
60	NULL
|	NULL
40	NULL
|	NULL
20	NULL
F	NULL
1	NULL
3	NULL
5	NULL
7	NULL
9	NULL
0	NULL
11	NULL
13	NULL
-	NULL
1500	NULL
17	NULL
survival	NULL
time	NULL
{	NULL
months	NULL
)	NULL
100	NULL
survival	NULL
rate	NULL
(	NULL
%	NULL
)	NULL
80	NULL
60	NULL
F	NULL
40	NULL
|	NULL
20	NULL
[	NULL
__	NULL
0	NULL
a	NULL
a	NULL
al	NULL
R	NULL
a	NULL
R	NULL
1	NULL
al	NULL
1	NULL
3	NULL
5	NULL
7	NULL
9	NULL
11	NULL
13	NULL
15	NULL
17	NULL
disease-free	NULL
survival	NULL
time	NULL
{	NULL
months	NULL
)	NULL
Fig	NULL
1	NULL
.	NULL

Overall	NULL
survival	NULL
(	NULL
top	NULL
)	NULL
and	NULL
disease-free	NULL
survival	NULL
(	NULL
bottom	NULL
)	NULL
curves	NULL
of	NULL
14	NULL
relapsed	NULL
APL	NULL
patients	NULL
after	NULL
As,0	NULL
;	NULL
-induced	NULL
CR	NULL
.	NULL

combination	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
(	NULL
28	NULL
to	NULL
54	NULL
days	NULL
and	NULL
hence	NULL
a	NULL
total	NULL
dose	NULL
of	NULL
280	NULL
to	NULL
540	NULL
mg	NULL
)	NULL
and	NULL
other	NULL
drugs	NULL
.	NULL

Three	NULL
patients	NULL
(	NULL
nos	NULL
.	NULL

11	NULL
,	NULL
13	NULL
,	NULL
15	NULL
)	NULL
with	NULL
a	NULL
WBC	NULL
count	NULL
over	NULL
30	NULL
x	NULL
10°/L	NULL
at	NULL
diagnosis	NULL
or	NULL
during	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
treatment	NULL
also	NULL
received	NULL
low-dose	NULL
chemotherapy	NULL
(	NULL
daunorubicin	NULL
,	NULL
cytosine	NULL
arabinoside	NULL
[	NULL
Ara-C	NULL
]	NULL
,	NULL
harringtonine	NULL
or	NULL
hydroxyurea	NULL
,	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

When	NULL
their	NULL
WBC	NULL
counts	NULL
declined	NULL
to	NULL
near	NULL
10	NULL
X	NULL
10°/L	NULL
,	NULL
chemotherapy	NULL
was	NULL
withdrawn	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
ATRA	NULL
(	NULL
30	NULL
mg/d	NULL
)	NULL
was	NULL
administered	NULL
in	NULL
two	NULL
cases	NULL
(	NULL
nos	NULL
.	NULL

12	NULL
and	NULL
14	NULL
)	NULL
due	NULL
to	NULL
leukopenia	NULL
.	NULL

Immediately	NULL
after	NULL
CR	NULL
,	NULL
PML-RARa	NULL
transcripts	NULL
were	NULL
examined	NULL
in	NULL
10	NULL
patients	NULL
.	NULL

All	NULL
but	NULL
one	NULL
(	NULL
no	NULL
.	NULL

6	NULL
)	NULL
were	NULL
still	NULL
positive	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
all	NULL
14	NULL
patients	NULL
were	NULL
followed	NULL
up	NULL
clinically	NULL
.	NULL

Figure	NULL
1	NULL
shows	NULL
that	NULL
four	NULL
patients	NULL
relapsed	NULL
at	NULL
months	NULL
4	NULL
,	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
.	NULL

Among	NULL
these	NULL
four	NULL
patients	NULL
,	NULL
two	NULL
died	NULL
at	NULL
months	NULL
5	NULL
and	NULL
9	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
other	NULL
10	NULL
patients	NULL
were	NULL
still	NULL
in	NULL
clinical	NULL
CR	NULL
.	NULL

Side	NULL
effects	NULL
.	NULL

-	NULL
Among	NULL
15	NULL
APL	NULL
patients	NULL
,	NULL
five	NULL
presented	NULL
increased	NULL
peripheral	NULL
WBC	NULL
count	NULL
with	NULL
the	NULL
peak	NULL
values	NULL
of	NULL
12.5	NULL
to	NULL
167	NULL
X	NULL
10°/L	NULL
.	NULL

The	NULL
time	NULL
to	NULL
reach	NULL
the	NULL
peak	NULL
WBC	NULL
numbers	NULL
after	NULL
the	NULL
initiation	NULL
of	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
treatment	NULL
was	NULL
14	NULL
to	NULL
42	NULL
days	NULL
(	NULL
medium	NULL
,	NULL
23	NULL
days	NULL
,	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

This	NULL
situation	NULL
seems	NULL
to	NULL
be	NULL
similar	NULL
to	NULL
the	NULL
clinical	NULL
picture	NULL
observed	NULL
after	NULL
ATRA	NULL
treatment	NULL
in	NULL
APL	NULL
patients	NULL
,	NULL
although	NULL
the	NULL
proportion	NULL
of	NULL
patients	NULL
displaying	NULL
hyperleucocytosis	NULL
is	NULL
much	NULL
higher	NULL
during	NULL
ATRA	NULL
remission	NULL
induction	NULL
(	NULL
80	NULL
%	NULL
to	NULL
90	NULL
%	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
changes	NULL
of	NULL
hemoglobin	NULL
(	NULL
Hb	NULL
)	NULL
and	NULL
platelet	NULL
levels	NULL
were	NULL
observed	NULL
in	NULL
nine	NULL
patients	NULL
,	NULL
but	NULL
six	NULL
patients	NULL
including	NULL
three	NULL
cases	NULL
(	NULL
nos	NULL
.	NULL

11	NULL
,	NULL
13	NULL
,	NULL
15	NULL
)	NULL
with	NULL
low-dose	NULL
chemotherapy	NULL
had	NULL
slightly	NULL
decreased	NULL
Hb	NULL
and	NULL
plate-let	NULL
.	NULL

Therefore	NULL
,	NULL
treatment	NULL
with	NULL
As	NULL
;	NULL
0	NULL
;	NULL
was	NULL
not	NULL
associated	NULL
with	NULL
significant	NULL
BM	NULL
suppression	NULL
.	NULL

In	NULL
line	NULL
with	NULL
this	NULL
,	NULL
the	NULL
in	NULL
vitro	NULL
SHEN	NULL
ET	NULL
AL	NULL
200	NULL
7	NULL
wWBC	NULL
(	NULL
X10	NULL
°/L	NULL
)	NULL
days	NULL
Fig	NULL
2	NULL
.	NULL

Dynamic	NULL
changes	NULL
of	NULL
peripheral	NULL
WBC	NULL
counts	NULL
during	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
in	NULL
five	NULL
patients	NULL
presenting	NULL
hyperleukocytosis	NULL
.	NULL

culture	NULL
of	NULL
two	NULL
normal	NULL
BM	NULL
samples	NULL
showed	NULL
relatively	NULL
low	NULL
inhibitory	NULL
effects	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
on	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
.	NULL

The	NULL
average	NULL
inhibition	NULL
rate	NULL
of	NULL
CFU-GM	NULL
was	NULL
31	NULL
%	NULL
and	NULL
that	NULL
of	NULL
CFU-E	NULL
was	NULL
28	NULL
%	NULL
.	NULL

Antigens	NULL
and/or	NULL
activities	NULL
of	NULL
some	NULL
coagulation	NULL
and	NULL
fibri-nolysis-related	NULL
proteins	NULL
were	NULL
systematically	NULL
measured	NULL
during	NULL
As	NULL
;	NULL
0	NULL
,	NULL
remission	NULL
induction	NULL
in	NULL
four	NULL
patients	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
FDP	NULL
and	NULL
D-D	NULL
dimers	NULL
were	NULL
rapidly	NULL
decreased	NULL
in	NULL
the	NULL
first	NULL
week	NULL
of	NULL
the	NULL
treatment	NULL
,	NULL
and	NULL
no	NULL
significant	NULL
alterations	NULL
of	NULL
other	NULL
parameters	NULL
were	NULL
observed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
principal	NULL
side	NULL
effects	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
3	NULL
.	NULL

Results	NULL
showed	NULL
that	NULL
the	NULL
most	NULL
common	NULL
side	NULL
effects	NULL
were	NULL
dermatologic	NULL
symptoms	NULL
such	NULL
as	NULL
itching	NULL
or	NULL
skin	NULL
erythematous	NULL
changes	NULL
(	NULL
26.7	NULL
%	NULL
)	NULL
and	NULL
gastrointestinal	NULL
symptoms	NULL
such	NULL
as	NULL
nausea	NULL
,	NULL
vomiting	NULL
,	NULL
and	NULL
loss	NULL
of	NULL
appetite	NULL
(	NULL
26.7	NULL
%	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
liver	NULL
function	NULL
tests	NULL
presented	NULL
moderate	NULL
alter	NULL
Table	NULL
3	NULL
.	NULL

Main	NULL
Side	NULL
Effects	NULL
With	NULL
As	NULL
;	NULL
0	NULL
;	NULL
Treatment	NULL
Frequency	NULL
Side	NULL
Effects	NULL
(	NULL
%	NULL
)	NULL
Skin	NULL
dryness	NULL
,	NULL
itching	NULL
,	NULL
or	NULL
erythematous	NULL
changes	NULL
26.7	NULL
(	NULL
4/15	NULL
)	NULL
Headache	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
EKG	NULL
change	NULL
(	NULL
1	NULL
)	NULL
low-flat	NULL
T-wave	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
(	NULL
2	NULL
)	NULL
sinal	NULL
tachycardia	NULL
and	NULL
I°	NULL
A-V	NULL
inductive	NULL
block	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
Nausea	NULL
,	NULL
vomiting	NULL
,	NULL
or	NULL
loss	NULL
of	NULL
appetite	NULL
accompanied	NULL
with	NULL
lassitude	NULL
26.7	NULL
(	NULL
4/15	NULL
)	NULL
Liver	NULL
function*	NULL
GPT	NULL
increased	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
GOT	NULL
increased	NULL
13.3	NULL
(	NULL
2/15	NULL
)	NULL
AKP	NULL
increased	NULL
13.3	NULL
(	NULL
2/15	NULL
)	NULL
y-GTP	NULL
increased	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
Total	NULL
bilirubin	NULL
increased	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
Enlargement	NULL
of	NULL
salivary	NULL
glandt	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
Thyrophyma	NULL
without	NULL
thyroidismt+	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
Arthralgia	NULL
or	NULL
musculogia	NULL
13.3	NULL
(	NULL
2/15	NULL
)	NULL
Teeth	NULL
ache	NULL
13.3	NULL
(	NULL
2/15	NULL
)	NULL
Oral	NULL
ulcer	NULL
6.7	NULL
(	NULL
1/15	NULL
)	NULL
Hemorrhage	NULL
of	NULL
teeth	NULL
,	NULL
nose	NULL
,	NULL
or	NULL
skin	NULL
13.3	NULL
(	NULL
2/15	NULL
)	NULL
These	NULL
signs	NULL
were	NULL
observed	NULL
in	NULL
*the	NULL
same	NULL
two	NULL
patients	NULL
,	NULL
tthe	NULL
same	NULL
patient	NULL
,	NULL
and	NULL
#	NULL
during	NULL
consolidation	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

EFFICACY	NULL
AND	NULL
PHARMACOKINETICS	NULL
OF	NULL
ARSENIC	NULL
IN	NULL
TREATING	NULL
APL	NULL
ations	NULL
such	NULL
as	NULL
increased	NULL
serum	NULL
hepatic	NULL
enzyme	NULL
levels	NULL
in	NULL
two	NULL
patients	NULL
.	NULL

EKG	NULL
changes	NULL
including	NULL
T-wave	NULL
change	NULL
and	NULL
I°	NULL
AV	NULL
block	NULL
were	NULL
seen	NULL
in	NULL
two	NULL
patients	NULL
.	NULL

Other	NULL
side	NULL
effects	NULL
,	NULL
usually	NULL
of	NULL
mild	NULL
nature	NULL
,	NULL
were	NULL
encountered	NULL
in	NULL
isolated	NULL
cases	NULL
.	NULL

All	NULL
these	NULL
manifestations	NULL
,	NULL
however	NULL
,	NULL
could	NULL
be	NULL
tolerated	NULL
by	NULL
the	NULL
patients	NULL
and/or	NULL
disappeared	NULL
rapidly	NULL
with	NULL
symptomatic	NULL
treatment	NULL
so	NULL
that	NULL
no	NULL
discontinuation	NULL
of	NULL
the	NULL
drug	NULL
was	NULL
needed	NULL
during	NULL
remission	NULL
induction	NULL
.	NULL

Pharmacokinetics	NULL
.	NULL

-	NULL
Plasma	NULL
pharmacokinetics	NULL
was	NULL
analyzed	NULL
at	NULL
the	NULL
first	NULL
day	NULL
of	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
remission	NULL
induction	NULL
in	NULL
eight	NULL
relapsed	NULL
APL	NULL
patients	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
plasma	NULL
arsenic	NULL
rapidly	NULL
reached	NULL
the	NULL
peak	NULL
level	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
,	NULL
with	NULL
the	NULL
mean	NULL
Cpmax	NULL
6.85	NULL
umol/L	NULL
(	NULL
range	NULL
,	NULL
5.54	NULL
to	NULL
7.30	NULL
umol/L	NULL
)	NULL
,	NULL
t1/2	NULL
«	NULL
0.89	NULL
+	NULL
0.29	NULL
hours	NULL
and	NULL
t1/28	NULL
12.13	NULL
+	NULL
3.31	NULL
hours	NULL
.	NULL

Detailed	NULL
pharmacokinetic	NULL
parameters	NULL
for	NULL
every	NULL
patient	NULL
analyzed	NULL
were	NULL
summarized	NULL
in	NULL
Table	NULL
4	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
possible	NULL
metabolic	NULL
changes	NULL
of	NULL
arsenic	NULL
after	NULL
its	NULL
long	NULL
time	NULL
use	NULL
,	NULL
pharmacokinetic	NULL
parameters	NULL
were	NULL
compared	NULL
between	NULL
day	NULL
1	NULL
and	NULL
day	NULL
30	NULL
of	NULL
the	NULL
remission	NULL
induction	NULL
in	NULL
three	NULL
patients	NULL
,	NULL
and	NULL
between	NULL
day	NULL
1	NULL
of	NULL
remission	NULL
induction	NULL
and	NULL
day	NULL
1	NULL
of	NULL
consolidation	NULL
therapy	NULL
,	NULL
which	NULL
was	NULL
administered	NULL
1	NULL
month	NULL
after	NULL
CR	NULL
,	NULL
in	NULL
two	NULL
patients	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
continuous	NULL
administration	NULL
of	NULL
arsenic	NULL
did	NULL
not	NULL
alter	NULL
its	NULL
pharmacokinetic	NULL
behaviors	NULL
and	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
alteration	NULL
of	NULL
plasma	NULL
concentration	NULL
of	NULL
arsenic	NULL
(	NULL
Fig	NULL
3B	NULL
and	NULL
C	NULL
,	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Arsenic	NULL
excretion	NULL
in	NULL
the	NULL
urine	NULL
and	NULL
accumulation	NULL
of	NULL
arsenic	NULL
in	NULL
peripheral	NULL
tissues	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
the	NULL
in	NULL
vivo	NULL
metabolism	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
,	NULL
contents	NULL
of	NULL
arsenic	NULL
in	NULL
urine	NULL
and	NULL
in	NULL
peripheral	NULL
tissues	NULL
(	NULL
nail	NULL
and	NULL
hair	NULL
)	NULL
were	NULL
measured	NULL
in	NULL
six	NULL
patients	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
urinary	NULL
arsenic	NULL
content	NULL
was	NULL
slightly	NULL
increased	NULL
during	NULL
drug	NULL
administration	NULL
and	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
arsenic	NULL
excreted	NULL
daily	NULL
in	NULL
the	NULL
urine	NULL
accounted	NULL
for	NULL
approximately	NULL
1	NULL
%	NULL
to	NULL
8	NULL
%	NULL
of	NULL
the	NULL
total	NULL
daily	NULL
dose	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
urinary	NULL
excretion	NULL
of	NULL
arsenic	NULL
persisted	NULL
after	NULL
withdrawal	NULL
of	NULL
the	NULL
drug	NULL
,	NULL
although	NULL
the	NULL
amount	NULL
excreted	NULL
was	NULL
slightly	NULL
de-creased	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
arsenic	NULL
contents	NULL
in	NULL
both	NULL
hair	NULL
and	NULL
nail	NULL
increased	NULL
gradually	NULL
and	NULL
the	NULL
peak	NULL
content	NULL
of	NULL
arsenic	NULL
could	NULL
reach	NULL
2.5	NULL
to	NULL
2.7	NULL
ug/g	NULL
at	NULL
CR	NULL
in	NULL
three	NULL
of	NULL
five	NULL
patients	NULL
tested	NULL
,	NULL
which	NULL
was	NULL
5	NULL
to	NULL
7	NULL
times	NULL
higher	NULL
than	NULL
that	NULL
(	NULL
0.35	NULL
to	NULL
0.40	NULL
ug/g	NULL
)	NULL
before	NULL
the	NULL
treatment	NULL
.	NULL

However	NULL
,	NULL
the	NULL
arsenic	NULL
content	NULL
of	NULL
hair	NULL
and	NULL
nail	NULL
could	NULL
be	NULL
decreased	NULL
in	NULL
the	NULL
interval	NULL
between	NULL
remission	NULL
induction	NULL
and	NULL
consolidation	NULL
,	NULL
as	NULL
well	NULL
as	NULL
after	NULL
consolidation	NULL
treatment	NULL
(	NULL
Fig	NULL
5A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
similar	NULL
changes	NULL
in	NULL
urinary	NULL
excretion	NULL
and	NULL
tissue	NULL
accumulation	NULL
were	NULL
observed	NULL
on	NULL
consolidation	NULL
therapy	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
remission	NULL
induction	NULL
(	NULL
Figs	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

DISCUSSION	NULL
In	NULL
late	NULL
1960s	NULL
and	NULL
early	NULL
1970s	NULL
,	NULL
a	NULL
group	NULL
of	NULL
doctors	NULL
from	NULL
Harbin	NULL
Medical	NULL
University	NULL
,	NULL
specialized	NULL
in	NULL
the	NULL
integration	NULL
of	NULL
Traditional	NULL
Chinese	NULL
Medicine	NULL
with	NULL
the	NULL
Western	NULL
Medicine	NULL
,	NULL
were	NULL
studying	NULL
effective	NULL
cancer	NULL
treatment	NULL
protocols	NULL
among	NULL
different	NULL
Chinese	NULL
medications	NULL
in	NULL
the	NULL
countryside	NULL
.	NULL

In	NULL
1970	NULL
,	NULL
they	NULL
got	NULL
a	NULL
remedy	NULL
in	NULL
a	NULL
family	NULL
practicing	NULL
traditional	NULL
medicine	NULL
,	NULL
which	NULL
seemed	NULL
to	NULL
be	NULL
effective	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
skin	NULL
cancer	NULL
.	NULL

After-ward	NULL
,	NULL
arsenic	NULL
stone	NULL
powder	NULL
was	NULL
found	NULL
to	NULL
be	NULL
the	NULL
effective	NULL
component	NULL
in	NULL
the	NULL
remedy	NULL
.	NULL

Since	NULL
there	NULL
were	NULL
no	NULL
other	NULL
protocols	NULL
available	NULL
for	NULL
cancer	NULL
patients	NULL
in	NULL
that	NULL
region	NULL
during	NULL
that	NULL
period	NULL
,	NULL
arsenic	NULL
was	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
different	NULL
cancers	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
soon	NULL
found	NULL
that	NULL
the	NULL
oral	NULL
administration	NULL
of	NULL
As	NULL
;	NULL
0	NULL
,	NULL
was	NULL
3357	NULL
8.0	NULL
6.0	NULL
4.0	NULL
2.0	NULL
\A	NULL
NM	NULL
~	NULL
>	NULL
0	NULL
+	NULL
T	NULL
T	NULL
@	NULL
)	NULL
E	NULL
0	NULL
10	NULL
20	NULL
30	NULL
E	NULL
hours	NULL
=t	NULL
B	NULL
O	NULL
|	NULL
7.0	NULL
+5	NULL
&	NULL
at	NULL
day	NULL
1	NULL
®	NULL
|	NULL
6.0	NULL
-+	NULL
at	NULL
day	NULL
30	NULL
pz	NULL
g	NULL
|	NULL
5.0	NULL
CJ	NULL
g	NULL
|	NULL
4.0	NULL
O	NULL
*	NULL
|_	NULL
3.0	NULL
w	NULL
ed	NULL
|	NULL
2.0	NULL
G	NULL
2	NULL
|	NULL
1.0	NULL
a	NULL
.	NULL

N	NULL
F	NULL
T	NULL
1	NULL
a	NULL
0	NULL
10	NULL
20	NULL
30	NULL
3	NULL
hours	NULL
m	NULL
C	NULL
+	NULL
remission	NULL
``	NULL
*	NULL
consolidation	NULL
20	NULL
30	NULL
hours	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Plasma	NULL
pharmacokinetic	NULL
curves	NULL
after	NULL
one	NULL
dose	NULL
(	NULL
10	NULL
mg	NULL
)	NULL
of	NULL
As	NULL
;	NULL
0	NULL
,	NULL
;	NULL
in	NULL
relapsed	NULL
APL	NULL
patients	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
mean	NULL
plasma	NULL
arsenic	NULL
concentration	NULL
time	NULL
curve	NULL
for	NULL
eight	NULL
patients	NULL
.	NULL

Bar	NULL
,	NULL
SD	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Pharmacokinetic	NULL
curves	NULL
obtained	NULL
on	NULL
day	NULL
1	NULL
and	NULL
day	NULL
30	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
remission	NULL
induction	NULL
in	NULL
patient	NULL
no	NULL
.	NULL

6	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Pharmacokinetic	NULL
curves	NULL
determined	NULL
on	NULL
day	NULL
1	NULL
of	NULL
remission	NULL
induction	NULL
and	NULL
day	NULL
1	NULL
of	NULL
consolidation	NULL
therapy	NULL
in	NULL
patient	NULL
no	NULL
.	NULL

13.	NULL
associated	NULL
with	NULL
severe	NULL
gastrointestinal	NULL
and	NULL
liver	NULL
side	NULL
effects	NULL
.	NULL

To	NULL
overcome	NULL
this	NULL
problem	NULL
,	NULL
the	NULL
drug	NULL
was	NULL
further	NULL
purified	NULL
in	NULL
order	NULL
to	NULL
make	NULL
a	NULL
solution	NULL
suitable	NULL
for	NULL
IV	NULL
administration	NULL
.	NULL

The	NULL
side	NULL
effects	NULL
were	NULL
significantly	NULL
reduced	NULL
and	NULL
this	NULL
form	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3358	NULL
Table	NULL
4	NULL
.	NULL

Pharmacokinetic	NULL
Parameters	NULL
After	NULL
Intravenous	NULL
Drip	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
in	NULL
Relapsed	NULL
APL	NULL
Patients	NULL
Patient	NULL
Cpmax	NULL
11/2e	NULL
11/28	NULL
Ve	NULL
CL	NULL
(	NULL
s	NULL
)	NULL
AUC	NULL
No	NULL
.	NULL

(	NULL
gmal/L	NULL
}	NULL
(	NULL
h	NULL
)	NULL
(	NULL
h	NULL
)	NULL
(	NULL
L	NULL
)	NULL
(	NULL
L/h	NULL
)	NULL
{	NULL
rmnol/h/L	NULL
}	NULL
6	NULL
6.01	NULL
0.55	NULL
6.38	NULL
3.83	NULL
1.38	NULL
36.20	NULL
6*	NULL
6.28	NULL
1.05	NULL
13.61	NULL
4.33	NULL
1.29	NULL
38.70	NULL
8	NULL
8.18	NULL
1.01	NULL
16.66	NULL
2.93	NULL
1.34	NULL
43.95	NULL
8t	NULL
6.22	NULL
0.87	NULL
11.26	NULL
3.82	NULL
1.40	NULL
35.70	NULL
9	NULL
7.10	NULL
0.49	NULL
12.36	NULL
3.44	NULL
1.27	NULL
39.55	NULL
9*	NULL
6.08	NULL
0.82	NULL
8.02	NULL
3.81	NULL
1.70	NULL
29.40	NULL
10	NULL
6.62	NULL
1.15	NULL
11.65	NULL
4.10	NULL
1.53	NULL
32.60	NULL
10*	NULL
6.22	NULL
1.00	NULL
10.03	NULL
4.31	NULL
1.49	NULL
34.30	NULL
11	NULL
6.82	NULL
0.62	NULL
10.46	NULL
3.98	NULL
1.43	NULL
34.85	NULL
12	NULL
5.54	NULL
0.93	NULL
11.17	NULL
4.30	NULL
1.81	NULL
27.60	NULL
13	NULL
6.62	NULL
1.16	NULL
16.52	NULL
4.15	NULL
1.33	NULL
37.55	NULL
13t	NULL
6.89	NULL
1.42	NULL
9.56	NULL
4.94	NULL
1.44	NULL
34.75	NULL
15	NULL
7.30	NULL
1.21	NULL
11.86	NULL
3.89	NULL
1.33	NULL
37.10	NULL
*	NULL
On	NULL
day	NULL
30	NULL
of	NULL
remission	NULL
induction	NULL
.	NULL

t	NULL
On	NULL
day	NULL
1	NULL
of	NULL
consolidation	NULL
treatment	NULL
.	NULL

has	NULL
been	NULL
used	NULL
,	NULL
since	NULL
March	NULL
1971	NULL
(	NULL
where	NULL
came	NULL
the	NULL
first	NULL
name	NULL
of	NULL
the	NULL
drug	NULL
,	NULL
713	NULL
)	NULL
in	NULL
the	NULL
clinical	NULL
trials	NULL
for	NULL
a	NULL
number	NULL
of	NULL
human	NULL
malignant	NULL
diseases	NULL
.	NULL

After	NULL
a	NULL
lengthy	NULL
study	NULL
in	NULL
more	NULL
than	NULL
1,000	NULL
patients	NULL
,	NULL
with	NULL
careful	NULL
examination	NULL
of	NULL
the	NULL
correlation	NULL
between	NULL
the	NULL
clinical	NULL
responses	NULL
and	NULL
different	NULL
cancer	NULL
types	NULL
,	NULL
a	NULL
few	NULL
cancers	NULL
have	NULL
been	NULL
found	NULL
to	NULL
be	NULL
good	NULL
targets	NULL
for	NULL
the	NULL
therapy	NULL
;	NULL
the	NULL
most	NULL
striking	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
APL	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
a	NULL
relatively	NULL
long	NULL
CR	NULL
duration	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
first	NULL
series	NULL
of	NULL
APL	NULL
patients	NULL
reported	NULL
by	NULL
Harbin	NULL
group	NULL
,	NULL
with	NULL
more	NULL
than	NULL
5-year	NULL
survival	NULL
in	NULL
half	NULL
of	NULL
the	NULL
patients	NULL
.	NULL
``	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
14	NULL
of	NULL
15	NULL
relapsed	NULL
APL	NULL
patients	NULL
,	NULL
SHEN	NULL
ET	NULL
AL	NULL
including	NULL
two	NULL
at	NULL
second	NULL
and	NULL
two	NULL
at	NULL
third	NULL
relapse	NULL
,	NULL
obtained	NULL
CR	NULL
after	NULL
using	NULL
As,0	NULL
;	NULL
.	NULL

This	NULL
result	NULL
is	NULL
of	NULL
particular	NULL
clinical	NULL
significance	NULL
,	NULL
since	NULL
previous	NULL
experiences	NULL
suggest	NULL
that	NULL
relapsed	NULL
APL	NULL
patients	NULL
have	NULL
relatively	NULL
poor	NULL
prognosis	NULL
.	NULL

According	NULL
to	NULL
a	NULL
recent	NULL
multicentric	NULL
study	NULL
in	NULL
China	NULL
,	NULL
the	NULL
remission	NULL
rate	NULL
with	NULL
ATRA	NULL
and/or	NULL
chemotherapy	NULL
in	NULL
patients	NULL
at	NULL
first	NULL
relapse	NULL
was	NULL
<	NULL
40	NULL
%	NULL
,	NULL
and	NULL
even	NULL
the	NULL
CR	NULL
duration	NULL
was	NULL
generally	NULL
short	NULL
.	NULL
``	NULL

As	NULL
;	NULL
0	NULL
;	NULL
,	NULL
may	NULL
have	NULL
no	NULL
significant	NULL
cross-resistance	NULL
to	NULL
the	NULL
currently	NULL
used	NULL
drugs	NULL
for	NULL
APL	NULL
,	NULL
because	NULL
all	NULL
these	NULL
patients	NULL
received	NULL
ATRA	NULL
and	NULL
chemotherapy	NULL
in	NULL
the	NULL
previous	NULL
remission	NULL
induction	NULL
and/or	NULL
postremissional	NULL
therapy	NULL
.	NULL

In	NULL
nine	NULL
patients	NULL
,	NULL
CR	NULL
was	NULL
obtained	NULL
with	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
alone	NULL
.	NULL

The	NULL
therapeutic	NULL
effect	NULL
of	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
can	NULL
thus	NULL
be	NULL
well	NULL
estab-lished	NULL
.	NULL

In	NULL
the	NULL
remaining	NULL
five	NULL
patients	NULL
,	NULL
drugs	NULL
other	NULL
than	NULL
As	NULL
;	NULL
0	NULL
;	NULL
were	NULL
also	NULL
used	NULL
to	NULL
deal	NULL
with	NULL
some	NULL
clinical	NULL
problems	NULL
.	NULL

For	NULL
example	NULL
,	NULL
chemotherapeutic	NULL
agents	NULL
were	NULL
used	NULL
in	NULL
three	NULL
cases	NULL
when	NULL
their	NULL
WBC	NULL
numbers	NULL
were	NULL
higher	NULL
than	NULL
30	NULL
%	NULL
10°/L	NULL
at	NULL
diagnosis	NULL
or	NULL
during	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
.	NULL

Being	NULL
used	NULL
at	NULL
low	NULL
dose	NULL
or	NULL
with	NULL
a	NULL
relatively	NULL
short	NULL
course	NULL
,	NULL
these	NULL
agents	NULL
were	NULL
unlikely	NULL
to	NULL
induce	NULL
CR	NULL
in	NULL
view	NULL
of	NULL
the	NULL
refractory	NULL
status	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

In	NULL
the	NULL
two	NULL
Japanese	NULL
patients	NULL
at	NULL
third	NULL
relapse	NULL
,	NULL
ATRA	NULL
was	NULL
used	NULL
as	NULL
``	NULL
supportive	NULL
'	NULL
``	NULL
'	NULL
treatment	NULL
throughout	NULL
remission	NULL
induction	NULL
.	NULL

Nevertheless	NULL
,	NULL
both	NULL
patients	NULL
were	NULL
previously	NULL
treated	NULL
with	NULL
ATRA	NULL
(	NULL
one	NULL
case	NULL
was	NULL
also	NULL
treated	NULL
with	NULL
AM-80	NULL
,	NULL
a	NULL
retinoid	NULL
derivative	NULL
)	NULL
and	NULL
no	NULL
response	NULL
was	NULL
observed	NULL
.	NULL

They	NULL
were	NULL
considered	NULL
as	NULL
being	NULL
resistant	NULL
to	NULL
both	NULL
conventional	NULL
chemotherapy	NULL
and	NULL
ATRA	NULL
when	NULL
referred	NULL
to	NULL
us	NULL
.	NULL

Although	NULL
there	NULL
seems	NULL
to	NULL
be	NULL
no	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
these	NULL
drugs	NULL
played	NULL
a	NULL
decisive	NULL
role	NULL
in	NULL
remission	NULL
induction	NULL
in	NULL
these	NULL
five	NULL
cases	NULL
,	NULL
however	NULL
,	NULL
we	NULL
can	NULL
not	NULL
completely	NULL
rule	NULL
out	NULL
their	NULL
contribution	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
concluded	NULL
that	NULL
CR	NULL
rate	NULL
should	NULL
be	NULL
90	NULL
%	NULL
(	NULL
9/10	NULL
)	NULL
.	NULL

ino	NULL
Lg	NULL
total	NULL
arsenic	NULL
contents	NULL
{	NULL
(	NULL
mg	NULL
)	NULL
in	NULL
24	NULL
hour	NULL
urine	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
Contents	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
excreted	NULL
every	NULL
24	NULL
hours	NULL
in	NULL
the	NULL
urine	NULL
among	NULL
six	NULL
patients	NULL
.	NULL

Arrows	NULL
point	NULL
out	NULL
the	NULL
time	NULL
when	NULL
drug	NULL
was	NULL
withdrawn	NULL
.	NULL

The	NULL
sign	NULL
``	NULL
*	NULL
``	NULL
marks	NULL
the	NULL
time	NULL
when	NULL
consolidation	NULL
therapy	NULL
was	NULL
be-gun	NULL
.	NULL

40	NULL
60	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

EFFICACY	NULL
AND	NULL
PHARMACOKINETICS	NULL
OF	NULL
ARSENIC	NULL
IN	NULL
TREATING	NULL
APL	NULL
hair	NULL
%	NULL
r	NULL
13	NULL
O	NULL
3	NULL
el	NULL
w	NULL
'D	NULL
To	NULL
lou	NULL
U	NULL
4	NULL
C	NULL
C	NULL
U	NULL
C	NULL
200	NULL
s	NULL
days	NULL
<	NULL
4	NULL
a	NULL
g	NULL
nail	NULL
hed	NULL
o	NULL
155	NULL
&	NULL
En	NULL
*13	NULL
3	NULL
.	NULL

-\\B\-\A	NULL
-	NULL
a	NULL
7	NULL
42	NULL
5	NULL
6	NULL
42	NULL
[	NULL
=	NULL
]	NULL
0	NULL
U	NULL
0	NULL
.	NULL

0	NULL
100	NULL
200	NULL
days	NULL
Fig	NULL
5	NULL
.	NULL

Dynamic	NULL
changes	NULL
of	NULL
As	NULL
;	NULL
0	NULL
,	NULL
;	NULL
contents	NULL
in	NULL
hair	NULL
(	NULL
A	NULL
)	NULL
and	NULL
nail	NULL
(	NULL
B	NULL
)	NULL
after	NULL
As,0	NULL
;	NULL
remission	NULL
induction	NULL
and/or	NULL
consolidation	NULL
treatment	NULL
in	NULL
APL	NULL
patients	NULL
.	NULL

The	NULL
number	NULL
at	NULL
the	NULL
end	NULL
of	NULL
each	NULL
curve	NULL
indicates	NULL
the	NULL
patient	NULL
case	NULL
number	NULL
.	NULL

Solid	NULL
lines	NULL
represent	NULL
the	NULL
time	NULL
when	NULL
patients	NULL
were	NULL
under	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
treatment	NULL
;	NULL
dotted	NULL
lines	NULL
correspond	NULL
to	NULL
the	NULL
days	NULL
when	NULL
drug	NULL
was	NULL
not	NULL
used	NULL
.	NULL

It	NULL
may	NULL
be	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
the	NULL
only	NULL
patient	NULL
in	NULL
this	NULL
study	NULL
who	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
,	NULL
had	NULL
no	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
nor	NULL
expression	NULL
of	NULL
the	NULL
PML-RAR	NULL
«	NULL
fusion	NULL
gene	NULL
transcripts	NULL
at	NULL
relapse	NULL
,	NULL
while	NULL
his	NULL
leukemic	NULL
cells	NULL
retained	NULL
typical	NULL
morphologic	NULL
features	NULL
of	NULL
APL	NULL
.	NULL

This	NULL
case	NULL
was	NULL
positive	NULL
for	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
and	NULL
PML-RARa	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
the	NULL
disease	NULL
and	NULL
a	NULL
first	NULL
CR	NULL
was	NULL
successfully	NULL
induced	NULL
with	NULL
ATRA	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
fusion	NULL
gene	NULL
transcript	NULL
reflects	NULL
either	NULL
a	NULL
secondary	NULL
oncogenic	NULL
activation	NULL
,	NULL
which	NULL
makes	NULL
the	NULL
PML-RARa	NULL
unnecessary	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
the	NULL
malignant	NULL
phenotype	NULL
,	NULL
or	NULL
a	NULL
selection	NULL
of	NULL
pre-existing	NULL
subclone	NULL
without	NULL
PML-RARa	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
clarified	NULL
whether	NULL
the	NULL
poor	NULL
response	NULL
to	NULL
As	NULL
;	NULL
0	NULL
;	NULL
treatment	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
PML-RARa	NULL
fusion	NULL
.	NULL

Clinical	NULL
observations	NULL
revealed	NULL
that	NULL
the	NULL
currently	NULL
used	NULL
dose	NULL
(	NULL
10	NULL
mg	NULL
)	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
through	NULL
IV	NULL
administration	NULL
resulted	NULL
in	NULL
only	NULL
mild	NULL
to	NULL
moderate	NULL
side	NULL
effects	NULL
.	NULL

First	NULL
,	NULL
As	NULL
;	NULL
O	NULL
;	NULL
treatment	NULL
did	NULL
not	NULL
cause	NULL
BM	NULL
suppression	NULL
and	NULL
did	NULL
not	NULL
exacerbate	NULL
bleeding	NULL
.	NULL

Instead	NULL
it	NULL
tended	NULL
to	NULL
improve	NULL
the	NULL
fibrinolytic	NULL
activation	NULL
status	NULL
(	NULL
either	NULL
3359	NULL
primary	NULL
or	NULL
secondary	NULL
to	NULL
the	NULL
increased	NULL
coagulability	NULL
)	NULL
in	NULL
the	NULL
patients	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
decreased	NULL
D-D	NULL
dimer	NULL
and	NULL
FDP	NULL
levels	NULL
.	NULL

Second	NULL
,	NULL
no	NULL
life-threatening	NULL
acute	NULL
toxicity	NULL
was	NULL
observed	NULL
.	NULL

It	NULL
was	NULL
reported	NULL
that	NULL
oral	NULL
administration	NULL
of	NULL
250	NULL
mg	NULL
(	NULL
twice	NULL
daily	NULL
or	NULL
three	NULL
times	NULL
daily	NULL
)	NULL
synthetic	NULL
or	NULL
mineral	NULL
arsenic	NULL
compounds	NULL
for	NULL
7	NULL
to	NULL
10	NULL
days	NULL
was	NULL
safe	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
amebiasis	NULL
.	NULL
'	NULL

''	NULL
The	NULL
lethal	NULL
dose	NULL
recorded	NULL
in	NULL
the	NULL
literatures	NULL
was	NULL
a	NULL
single	NULL
dose	NULL
of	NULL
more	NULL
than	NULL
100	NULL
mg	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
our	NULL
previous	NULL
results	NULL
demonstrating	NULL
that	NULL
LDs	NULL
,	NULL
of	NULL
0.1	NULL
%	NULL
As	NULL
;	NULL
0	NULL
;	NULL
solution	NULL
in	NULL
ICR	NULL
mice	NULL
was	NULL
9.43	NULL
mg/kg	NULL
body	NULL
weight	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Pharmacokinetics	NULL
showed	NULL
that	NULL
plasma	NULL
arsenic	NULL
was	NULL
rapidly	NULL
eliminated	NULL
and	NULL
continuous	NULL
administration	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
accumulation	NULL
of	NULL
arsenic	NULL
in	NULL
plasma	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
95	NULL
%	NULL
to	NULL
97	NULL
%	NULL
of	NULL
blood	NULL
arsenic	NULL
is	NULL
bound	NULL
to	NULL
hemoglobin	NULL
and	NULL
can	NULL
be	NULL
distributed	NULL
rapidly	NULL
into	NULL
some	NULL
tissues	NULL
and	NULL
organs	NULL
.	NULL

After	NULL
entrance	NULL
into	NULL
human	NULL
body	NULL
,	NULL
the	NULL
accumulation	NULL
of	NULL
arsenic	NULL
mainly	NULL
occurs	NULL
in	NULL
tissues	NULL
rich	NULL
in	NULL
sulfydryl	NULL
group-containing	NULL
proteins	NULL
such	NULL
as	NULL
hair	NULL
,	NULL
nail	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
.	NULL
``	NULL

To	NULL
evaluate	NULL
the	NULL
in	NULL
vivo	NULL
excretion	NULL
and	NULL
accumulation	NULL
of	NULL
arsenic	NULL
,	NULL
arsenic	NULL
contents	NULL
in	NULL
urine	NULL
and	NULL
peripheral	NULL
tissues	NULL
were	NULL
measured	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
daily	NULL
urinary	NULL
excretion	NULL
of	NULL
arsenic	NULL
accounted	NULL
for	NULL
only	NULL
a	NULL
very	NULL
low	NULL
percentage	NULL
(	NULL
approxi-mately	NULL
1	NULL
%	NULL
to	NULL
8	NULL
%	NULL
)	NULL
of	NULL
the	NULL
total	NULL
daily	NULL
dose	NULL
used	NULL
.	NULL

It	NULL
is	NULL
still	NULL
to	NULL
be	NULL
determined	NULL
whether	NULL
other	NULL
pathways	NULL
can	NULL
make	NULL
an	NULL
important	NULL
contribution	NULL
to	NULL
the	NULL
elimination	NULL
of	NULL
the	NULL
drug	NULL
administered	NULL
IV	NULL
.	NULL

According	NULL
to	NULL
the	NULL
report	NULL
by	NULL
Nielsen	NULL
and	NULL
Uthus	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
arsenic	NULL
excreted	NULL
in	NULL
the	NULL
stool	NULL
(	NULL
900	NULL
g/d	NULL
)	NULL
is	NULL
far	NULL
more	NULL
than	NULL
that	NULL
excreted	NULL
by	NULL
urine	NULL
(	NULL
50	NULL
ug/d	NULL
)	NULL
,	NULL
'	NULL
suggesting	NULL
that	NULL
gastrointestinal	NULL
tract	NULL
may	NULL
be	NULL
one	NULL
of	NULL
the	NULL
main	NULL
pathways	NULL
for	NULL
in	NULL
vivo	NULL
arsenic	NULL
excretion	NULL
.	NULL

As	NULL
a	NULL
matter	NULL
of	NULL
fact	NULL
,	NULL
in	NULL
our	NULL
series	NULL
,	NULL
although	NULL
arsenic	NULL
contents	NULL
in	NULL
hair	NULL
and	NULL
nail	NULL
of	NULL
the	NULL
patients	NULL
increased	NULL
gradually	NULL
during	NULL
continuous	NULL
administration	NULL
and	NULL
the	NULL
contents	NULL
of	NULL
arsenic	NULL
in	NULL
these	NULL
tissues	NULL
were	NULL
five	NULL
to	NULL
seven	NULL
times	NULL
that	NULL
before	NULL
treatment	NULL
(	NULL
0.35	NULL
to	NULL
0.40	NULL
ug/g	NULL
)	NULL
,	NULL
the	NULL
peak	NULL
levels	NULL
(	NULL
2.0	NULL
to	NULL
2.7	NULL
ug/	NULL
g	NULL
nail	NULL
)	NULL
were	NULL
still	NULL
below	NULL
the	NULL
upper	NULL
limit	NULL
reported	NULL
in	NULL
normal	NULL
individuals	NULL
(	NULL
3	NULL
pg/g	NULL
)	NULL
.	NULL
'	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
arsenic	NULL
in	NULL
hair	NULL
and	NULL
nail	NULL
tends	NULL
to	NULL
decrease	NULL
,	NULL
whereas	NULL
the	NULL
urinary	NULL
excretion	NULL
of	NULL
the	NULL
drug	NULL
tends	NULL
to	NULL
continue	NULL
after	NULL
withdrawal	NULL
of	NULL
the	NULL
drug	NULL
.	NULL

These	NULL
observations	NULL
may	NULL
further	NULL
explain	NULL
why	NULL
IV	NULL
infusion	NULL
of	NULL
10	NULL
mg/d	NULL
As	NULL
;	NULL
0	NULL
;	NULL
,	NULL
was	NULL
relatively	NULL
safe	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
APL	NULL
.	NULL

It	NULL
should	NULL
be	NULL
pointed	NULL
out	NULL
that	NULL
the	NULL
long-term	NULL
effect	NULL
of	NULL
As	NULL
;	NULL
0	NULL
;	NULL
needs	NULL
further	NULL
investigation	NULL
,	NULL
despite	NULL
the	NULL
reports	NULL
of	NULL
long	NULL
time	NULL
survival	NULL
.	NULL

Therefore	NULL
,	NULL
at	NULL
this	NULL
time	NULL
,	NULL
we	NULL
prefer	NULL
to	NULL
recommend	NULL
As	NULL
;	NULL
0	NULL
;	NULL
as	NULL
a	NULL
second	NULL
line	NULL
drug	NULL
,	NULL
and	NULL
its	NULL
use	NULL
should	NULL
be	NULL
reserved	NULL
for	NULL
APL	NULL
patients	NULL
refractory	NULL
to	NULL
ATRA	NULL
and	NULL
conventional	NULL
che-motherapy	NULL
.	NULL

If	NULL
the	NULL
relative	NULL
safety	NULL
of	NULL
its	NULL
long	NULL
term	NULL
use	NULL
can	NULL
be	NULL
assured	NULL
in	NULL
the	NULL
future	NULL
,	NULL
As,0	NULL
;	NULL
may	NULL
be	NULL
incorporated	NULL
into	NULL
a	NULL
multidrug	NULL
protocol	NULL
for	NULL
de	NULL
novo	NULL
patients	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Prof	NULL
L.	NULL
Degos	NULL
from	NULL
Saint-Louis	NULL
Hospital	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
;	NULL
Prof	NULL
R.	NULL
Ohno	NULL
from	NULL
Hamamatsu	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Japan	NULL
;	NULL
and	NULL
Prof	NULL
S.	NULL
Waxman	NULL
from	NULL
Mount	NULL
Sinai	NULL
Medical	NULL
Center	NULL
,	NULL
NY	NULL
,	NULL
for	NULL
constructive	NULL
discussion	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Nielsen	NULL
FH	NULL
,	NULL
Uthus	NULL
EO	NULL
:	NULL
Arsenic	NULL
,	NULL
in	NULL
Frieden	NULL
F	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
Biochemistry	NULL
of	NULL
the	NULL
Essential	NULL
Ultratrace	NULL
Elements	NULL
.	NULL

New	NULL
York	NULL
,	NULL
Plenum	NULL
,	NULL
NY	NULL
1981	NULL
,	NULL
p	NULL
319	NULL
2	NULL
.	NULL

Bishop	NULL
C	NULL
,	NULL
Kipling	NULL
MD	NULL
:	NULL
Arsenic	NULL
and	NULL
cancer	NULL
.	NULL

J	NULL
Soc	NULL
Occup	NULL
Med	NULL
28:3	NULL
,	NULL
1978	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3360	NULL
3	NULL
.	NULL

Dong	NULL
JT	NULL
,	NULL
Luo	NULL
XM	NULL
:	NULL
Effects	NULL
of	NULL
arsenic	NULL
on	NULL
DNA	NULL
damage	NULL
and	NULL
repair	NULL
in	NULL
human	NULL
fetal	NULL
lung	NULL
fibroblasts	NULL
.	NULL

Mutat	NULL
Res	NULL
315:11	NULL
,	NULL
1994	NULL
4	NULL
.	NULL

Lee	NULL
TC	NULL
,	NULL
Oshimura	NULL
M	NULL
,	NULL
Barrent	NULL
JC	NULL
:	NULL
Comparison	NULL
of	NULL
arsenic-induced	NULL
cell	NULL
transformation	NULL
,	NULL
cytotoxicity	NULL
,	NULL
mutation	NULL
and	NULL
cytogenetic	NULL
effects	NULL
in	NULL
Syrian	NULL
hamster	NULL
embryo	NULL
cells	NULL
in	NULL
culture	NULL
.	NULL

Carcinogenesis	NULL
6:1421	NULL
,	NULL
1985	NULL
5	NULL
.	NULL

Lerda	NULL
D	NULL
:	NULL
Sister-chromatid	NULL
exchange	NULL
(	NULL
SCE	NULL
)	NULL
among	NULL
individuals	NULL
chronically	NULL
exposed	NULL
to	NULL
arsenic	NULL
in	NULL
drinking	NULL
water	NULL
.	NULL

Mutat	NULL
Res	NULL
312:111	NULL
,	NULL
1994	NULL
6	NULL
.	NULL

Chen	NULL
ZY	NULL
,	NULL
Liu	NULL
TP	NULL
,	NULL
Yang	NULL
Y	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Manual	NULL
of	NULL
Clinical	NULL
Drugs	NULL
.	NULL

Shanghai	NULL
,	NULL
China	NULL
,	NULL
Shanghai	NULL
Science	NULL
and	NULL
Technology	NULL
,	NULL
1995	NULL
,	NULL
p	NULL
830	NULL
7	NULL
.	NULL

Correia	NULL
MA	NULL
,	NULL
Becker	NULL
CE	NULL
:	NULL
Chelators	NULL
and	NULL
heavy	NULL
metal	NULL
intoxica-tion	NULL
,	NULL
in	NULL
Katzung	NULL
BG	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Basic	NULL
and	NULL
Clinical	NULL
Pharmacology	NULL
,	NULL
fourth	NULL
ed	NULL
.	NULL

London	NULL
,	NULL
UK	NULL
,	NULL
Prentice-Hall	NULL
,	NULL
1989	NULL
,	NULL
p	NULL
747	NULL
8	NULL
.	NULL

Finch	NULL
RG	NULL
,	NULL
Snyder	NULL
IS	NULL
:	NULL
Antiprotozoal	NULL
drugs	NULL
,	NULL
in	NULL
Craig	NULL
CR	NULL
,	NULL
Stitzel	NULL
RE	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Modern	NULL
Pharmacology	NULL
.	NULL

Boston	NULL
,	NULL
MA	NULL
,	NULL
Little	NULL
,	NULL
Brown	NULL
,	NULL
1982	NULL
,	NULL
p	NULL
698	NULL
9	NULL
.	NULL

Sun	NULL
HD	NULL
,	NULL
Ma	NULL
L	NULL
,	NULL
Hu	NULL
XC	NULL
,	NULL
Zhang	NULL
TD	NULL
:	NULL
Ai-Lin	NULL
I	NULL
treated	NULL
32	NULL
cases	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Chin	NULL
J	NULL
Integrat	NULL
Chin	NULL
&	NULL
West	NULL
Med	NULL
12:170	NULL
,	NULL
1992	NULL
10	NULL
.	NULL

Zhang	NULL
P	NULL
,	NULL
Wang	NULL
SY	NULL
,	NULL
Hu	NULL
LH	NULL
,	NULL
Shi	NULL
FD	NULL
,	NULL
Qiu	NULL
FQ	NULL
,	NULL
Hong	NULL
GJ	NULL
,	NULL
Han	NULL
XY	NULL
,	NULL
Yang	NULL
HF	NULL
,	NULL
Sun	NULL
YZ	NULL
,	NULL
Liu	NULL
YP	NULL
,	NULL
Zhao	NULL
J	NULL
,	NULL
Jin	NULL
ZJ	NULL
:	NULL
Arsenic	NULL
trioxide	NULL
treated	NULL
72	NULL
cases	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Chin	NULL
J	NULL
Hematol	NULL
2:58	NULL
,	NULL
1996	NULL
11	NULL
.	NULL

Wang	NULL
ZY	NULL
:	NULL
To	NULL
develop	NULL
clinical	NULL
and	NULL
experimental	NULL
studies	NULL
for	NULL
arsenic	NULL
to	NULL
treat	NULL
leukemia	NULL
.	NULL

Chinese	NULL
J	NULL
Hematol	NULL
2:56	NULL
,	NULL
1996	NULL
SHEN	NULL
ET	NULL
AL	NULL
12	NULL
.	NULL

Huang	NULL
W	NULL
,	NULL
Sun	NULL
GL	NULL
,	NULL
Li	NULL
XS	NULL
,	NULL
Cao	NULL
Q	NULL
,	NULL
Lu	NULL
Y	NULL
,	NULL
Jang	NULL
GS	NULL
,	NULL
Zhang	NULL
FQ	NULL
,	NULL
Chai	NULL
JR	NULL
,	NULL
Wang	NULL
ZY	NULL
,	NULL
Waxman	NULL
S	NULL
,	NULL
Chen	NULL
Z	NULL
,	NULL
Chen	NULL
SJ	NULL
:	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
Clinical	NULL
relevance	NULL
of	NULL
two	NULL
major	NULL
PML-RARa	NULL
isoforms	NULL
and	NULL
detection	NULL
of	NULL
minimal	NULL
residual	NULL
disease	NULL
by	NULL
RT-PCR	NULL
to	NULL
predict	NULL
relapse	NULL
.	NULL

Blood	NULL
82:1264	NULL
,	NULL
1993	NULL
13	NULL
.	NULL

Chen	NULL
GQ	NULL
,	NULL
Zhu	NULL
J	NULL
,	NULL
Shi	NULL
XG	NULL
,	NULL
Zhong	NULL
HJ	NULL
,	NULL
Ni	NULL
JH	NULL
,	NULL
Si	NULL
GY	NULL
,	NULL
Jin	NULL
XL	NULL
,	NULL
Tang	NULL
W	NULL
,	NULL
Li	NULL
XS	NULL
,	NULL
Xong	NULL
SM	NULL
,	NULL
Shen	NULL
ZX	NULL
,	NULL
Ma	NULL
J	NULL
,	NULL
Zhang	NULL
P	NULL
,	NULL
Zhang	NULL
TD	NULL
,	NULL
Claude	NULL
Gazin	NULL
,	NULL
Nace	NULL
T	NULL
,	NULL
Chen	NULL
SJ	NULL
,	NULL
Wang	NULL
ZY	NULL
,	NULL
Chen	NULL
Z	NULL
:	NULL
In	NULL
vitro	NULL
studies	NULL
on	NULL
cellular	NULL
and	NULL
molecular	NULL
mechanisms	NULL
of	NULL
arsenic	NULL
trioxide	NULL
(	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
)	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
As	NULL
;	NULL
,0	NULL
;	NULL
induces	NULL
NB	NULL
,	NULL
cell	NULL
apoptosis	NULL
with	NULL
down-regulation	NULL
of	NULL
Bel-2	NULL
expression	NULL
and	NULL
alteration	NULL
of	NULL
PML-RAR	NULL
@	NULL
/PML	NULL
protein	NULL
localization	NULL
.	NULL

Blood	NULL
88:1052	NULL
,	NULL
1996	NULL
14	NULL
.	NULL

Chen	NULL
GQ	NULL
,	NULL
Shen	NULL
ZX	NULL
,	NULL
Wu	NULL
F	NULL
,	NULL
Han	NULL
JY	NULL
,	NULL
Miao	NULL
JM	NULL
,	NULL
Zhong	NULL
HJ	NULL
,	NULL
Li	NULL
XS	NULL
,	NULL
Zhao	NULL
JQ	NULL
,	NULL
Zhu	NULL
J	NULL
,	NULL
Fang	NULL
ZW	NULL
,	NULL
Chen	NULL
SJ	NULL
,	NULL
Chen	NULL
Z	NULL
,	NULL
Wang	NULL
ZY	NULL
:	NULL
Pharmacokinetics	NULL
and	NULL
efficacy	NULL
of	NULL
low-dose	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
10:825	NULL
,	NULL
1996	NULL
15	NULL
.	NULL

Sun	NULL
GL	NULL
,	NULL
OuYang	NULL
RR	NULL
,	NULL
Chen	NULL
SJ	NULL
,	NULL
Gu	NULL
LJ	NULL
,	NULL
Xie	NULL
WY	NULL
,	NULL
Zhang	NULL
FQ	NULL
,	NULL
Li	NULL
XS	NULL
,	NULL
Zhong	NULL
DH	NULL
,	NULL
Cai	NULL
JR	NULL
,	NULL
Chen	NULL
Z	NULL
,	NULL
Wang	NULL
ZY	NULL
,	NULL
Lu	NULL
JX	NULL
,	NULL
Huang	NULL
LA	NULL
,	NULL
Qian	NULL
ZC	NULL
,	NULL
Yu	NULL
HQ	NULL
,	NULL
Wang	NULL
YL	NULL
:	NULL
Treatment	NULL
of	NULL
APL	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
:	NULL
A	NULL
report	NULL
of	NULL
five-year	NULL
experience	NULL
.	NULL

Chin	NULL
J	NULL
Cancer	NULL
11:125	NULL
,	NULL
1993	NULL
16	NULL
.	NULL

Patterson	NULL
HR	NULL
,	NULL
Gustafson	NULL
EA	NULL
,	NULL
Sheridan	NULL
E	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Current	NULL
Drug	NULL
Handbook	NULL
1982-1984	NULL
.	NULL

Philadelphia	NULL
,	NULL
PA	NULL
,	NULL
Saunders	NULL
,	NULL
1982	NULL
,	NULL
p	NULL
50	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1997	NULL
89	NULL
:	NULL
3354-3360	NULL
Use	NULL
of	NULL
Arsenic	NULL
Trioxide	NULL
)	NULL
in	NULL
the	NULL
Treatment	NULL
of	NULL
Acute	NULL
Promyelocytic	NULL
Leukemia	NULL
(	NULL
APL	NULL
)	NULL
:	NULL
II	NULL
.	NULL

Clinical	NULL
Efﬁcacy	NULL
and	NULL
Pharmacokinetics	NULL
in	NULL
Relapsed	NULL
Patients	NULL
A	NULL
_	NULL
48	NULL
o	NULL
6	NULL
'	NULL
t	NULL
\se	NULL
@	NULL
.	NULL

/	NULL
{	NULL
®	NULL
Zhi-Xiang	NULL
Shen	NULL
,	NULL
Guo-Qiang	NULL
Chen	NULL
,	NULL
Jian-Hua	NULL
Ni	NULL
,	NULL
Xiu-Shong	NULL
Li	NULL
,	NULL
Shu-Min	NULL
Xiong	NULL
,	NULL
Qian-Yao	NULL
Qiu	NULL
,	NULL
Jun	NULL
Zhu	NULL
,	NULL
Wei	NULL
Tang	NULL
,	NULL
Guan-Lin	NULL
Sun	NULL
,	NULL
Kan-Qi	NULL
Yang	NULL
,	NULL
Yu	NULL
Chen	NULL
,	NULL
Li	NULL
Zhou	NULL
,	NULL
Zhi-Wen	NULL
Fang	NULL
,	NULL
Yan-Ting	NULL
Wang	NULL
,	NULL
Jun	NULL
Ma	NULL
,	NULL
Peng	NULL
Zhang	NULL
,	NULL
Ting-Dong	NULL
Zhang	NULL
,	NULL
Sai-Juan	NULL
Chen	NULL
,	NULL
Zhu	NULL
Chen	NULL
and	NULL
Zhen-Y¥i	NULL
Wang	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/89/9/3354.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Neoplasia	NULL
(	NULL
4182	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

